Tags

Type your tag names separated by a space and hit enter

Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.
Paediatr Drugs. 2005; 7(2):123-36.PD

Abstract

OBJECTIVE

Pertussis is a frequent cause of cough illness in adolescents. In Canada, immunization against pertussis in public programs has been restricted to children under 7 years of age. The purpose of this analysis was to estimate the health and economic impact of an additional booster dose of the acellular vaccine in adolescents in Québec.

METHOD

We performed a cost-effectiveness analysis, based on a predictive spreadsheet dynamic model following a cohort of 90,929 adolescents in Québec from the age of 14 years over a 10-year period from the Québec Ministry of Health (MOH) and societal (SOC) perspectives. The model was used to compare costs (2003 values) and benefits of an adolescent vaccination program (AVP), including a diptheria, tetanus, and acellular pertussis (dTacp) vaccine administered at age 14 years, with current practice.

RESULTS

From the MOH perspective, a booster vaccination of dTacp at age 14 years via the AVP would produce a yearly additional expected cost of Can dollars 1.06 per adolescent with an incremental cost-effectiveness ratio (ICER) of Can dollars 480 per pertussis case avoided based on a 10-year period. When outcomes are discounted at 3%, the ICER rises to Can dollars 527 per discounted pertussis case avoided. From the SOC perspective, the AVP would cost Can dollars 0.83 per adolescent per year with an additional cost per avoided pertussis case of Can dollars 377 (Can dollars 414 per additional discounted case of pertussis avoided). Over the 10-year period, 2012 non-discounted cases of pertussis would be prevented with approximately two hospital admissions averted.

CONCLUSION

This study suggests that administering a booster dose of dTacp at age 14 years to replace the diptheria and tetanus vaccination will slightly increase the economic burden from MOH and SOC perspectives; however, the number of pertussis cases and the number of hospital admissions will decrease.

Authors+Show Affiliations

PharmIdeas Research and Consulting Inc., Oakville, Ontario, Canada. skedji@pharmideas.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15871632

Citation

Iskedjian, Michael, et al. "Economic Evaluation of an Extended Acellular Pertussis Vaccine Program for Adolescents in Québec, Canada." Paediatric Drugs, vol. 7, no. 2, 2005, pp. 123-36.
Iskedjian M, Walker JH, De Serres G, et al. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada. Paediatr Drugs. 2005;7(2):123-36.
Iskedjian, M., Walker, J. H., De Serres, G., & Einarson, T. R. (2005). Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada. Paediatric Drugs, 7(2), 123-36.
Iskedjian M, et al. Economic Evaluation of an Extended Acellular Pertussis Vaccine Program for Adolescents in Québec, Canada. Paediatr Drugs. 2005;7(2):123-36. PubMed PMID: 15871632.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada. AU - Iskedjian,Michael, AU - Walker,John H, AU - De Serres,Gaston, AU - Einarson,Thomas R, PY - 2005/5/6/pubmed PY - 2006/4/11/medline PY - 2005/5/6/entrez SP - 123 EP - 36 JF - Paediatric drugs JO - Paediatr Drugs VL - 7 IS - 2 N2 - OBJECTIVE: Pertussis is a frequent cause of cough illness in adolescents. In Canada, immunization against pertussis in public programs has been restricted to children under 7 years of age. The purpose of this analysis was to estimate the health and economic impact of an additional booster dose of the acellular vaccine in adolescents in Québec. METHOD: We performed a cost-effectiveness analysis, based on a predictive spreadsheet dynamic model following a cohort of 90,929 adolescents in Québec from the age of 14 years over a 10-year period from the Québec Ministry of Health (MOH) and societal (SOC) perspectives. The model was used to compare costs (2003 values) and benefits of an adolescent vaccination program (AVP), including a diptheria, tetanus, and acellular pertussis (dTacp) vaccine administered at age 14 years, with current practice. RESULTS: From the MOH perspective, a booster vaccination of dTacp at age 14 years via the AVP would produce a yearly additional expected cost of Can dollars 1.06 per adolescent with an incremental cost-effectiveness ratio (ICER) of Can dollars 480 per pertussis case avoided based on a 10-year period. When outcomes are discounted at 3%, the ICER rises to Can dollars 527 per discounted pertussis case avoided. From the SOC perspective, the AVP would cost Can dollars 0.83 per adolescent per year with an additional cost per avoided pertussis case of Can dollars 377 (Can dollars 414 per additional discounted case of pertussis avoided). Over the 10-year period, 2012 non-discounted cases of pertussis would be prevented with approximately two hospital admissions averted. CONCLUSION: This study suggests that administering a booster dose of dTacp at age 14 years to replace the diptheria and tetanus vaccination will slightly increase the economic burden from MOH and SOC perspectives; however, the number of pertussis cases and the number of hospital admissions will decrease. SN - 1174-5878 UR - https://www.unboundmedicine.com/medline/citation/15871632/Economic_evaluation_of_an_extended_acellular_pertussis_vaccine_program_for_adolescents_in_Québec_Canada_ L2 - https://dx.doi.org/10.2165/00148581-200507020-00005 DB - PRIME DP - Unbound Medicine ER -